2.24
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Moleculin Announces Closing of up to $16.5 Million Public Offering - Quantisnow
MBRX Should I Buy - Intellectia AI
MBRX PE Ratio & Valuation, Is MBRX Overvalued - Intellectia AI
Moleculin Biotech (MBRX) seeks OK for 6.37M warrants, $15.3M proceeds - Stock Titan
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Moleculin Biotech Inc. forming higher highs and higher lowsJuly 2025 Reactions & Community Trade Idea Sharing Platform - mfd.ru
Moleculin Biotech Raises Capital via Inducement Warrant Agreements - TipRanks
Why Moleculin Biotech Inc. stock remains on buy listsDollar Strength & Daily Entry Point Trade Alerts - mfd.ru
Moleculin Biotech Secures Up To $8.3 Million Via Warrant Exercise; Issues 300% Series H Warrants - TradingView
Moleculin Biotech Exercises Warrants for $8.3M - Intellectia AI
Moleculin Biotech raises $8.3 million through warrant exercise By Investing.com - Investing.com Canada
Moleculin shares slide sharply after warrant exercise deal - MSN
Aug Intraday: Can Moleculin Biotech Inc maintain sales growth2025 Price Momentum & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Moleculin Stock Plunges On $8.3 Million Warrant Exercise - Nasdaq
Moleculin Biotech stock plunges after warrant exercise agreement By Investing.com - Investing.com Nigeria
Moleculin Biotech stock plunges after warrant exercise agreement - Investing.com South Africa
Moleculin Biotech raises $8.3 million through warrant exercise - Investing.com
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds - The Manila Times
Moleculin Biotech, Inc. Announces Agreement for Immediate Exercise of Warrants to Raise Approximately $8.3 Million - Quiver Quantitative
Moleculin reports promising early data in pivotal AML treatment trial By Investing.com - Investing.com India
Moleculin Biotech Issues New Investor Corporate Presentation - TipRanks
Moleculin Biotech (MBRX) Nears Key Milestone in Leukemia Trial P - GuruFocus
Moleculin Biotech stock rises as AML drug trial shows promising results - Investing.com Nigeria
Moleculin Biotech stock rises as AML drug trial shows promising results By Investing.com - Investing.com Canada
Moleculin Reports Positive Progress in MIRACLE AML Trial - TipRanks
Moleculin reports promising early data in pivotal AML treatment trial - Investing.com
Moleculin reports 40% preliminary CRc in MIRACLE trial; 35 treated, 45-subject unblinding on track - TradingView
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) - GlobeNewswire
Moleculin receives patent allowance in Japan for Annamycin preparation method - Investing.com India
Moleculin Biotech Receives Patent Allowance from Japan Patent Office - Intellectia AI
Profit Recap: What are Moleculin Biotech Incs earnings expectations2025 Dividend Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Moleculin Biotech stock rises after securing key Japanese patent - Investing.com
Moleculin Biotech stock rises after securing key Japanese patent By Investing.com - Investing.com India
Moleculin Biotech Says Japan Patent Office Issues Notice of Allowance for Patent Covering Annamycin; Shares Rise Pre-Bell - marketscreener.com
Moleculin Biotech (MBRX) Gains Japanese Patent Progress for Lipo - GuruFocus
Moleculin Gains Japanese Patent Allowance for Annamycin - TipRanks
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin - The Manila Times
Moleculin Biotech, Inc. Receives Notice of Allowance for Japanese Patent on Liposomal Annamycin Preparation Methods - Quiver Quantitative
Can Moleculin Biotech Inc. deliver consistent dividendsJuly 2025 Patterns & Reliable Intraday Trade Alerts - mfd.ru
Moleculin launches CEO Corner to enhance investor communication By Investing.com - Investing.com India
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):